



Review Article

Nocturia, nocturnal polyuria, and nocturnal enuresis in adults: What we know and what we do not know

Tien-Lin Chang, Hann-Chorng Kuo*

Department of Urology, Hualien
Tzu Chi Hospital, Buddhist Tzu
Chi Medical Foundation and Tzu
Chi University, Hualien, Taiwan

Submission : 27-Feb-2024
Revision : 29-Mar-2024
Acceptance : 13-Apr-2024
Web Publication : 27-May-2024

ABSTRACT

Nocturia is defined as the nocturnal frequency of one or more voiding episodes per night. It increases with aging and has an impact on sleep quality and the risks of falling and mortality. Nocturia disorder involves nighttime frequency, nocturnal polyuria, and nocturnal enuresis. In older adults with nocturia disorder, multiple factors could contribute to nocturia severity and characteristics, including poor sleep quality, lower urinary tract dysfunction, and excessive fluid output. Several nonurological medical diseases have been found to result in nocturia, such as hypertension, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, metabolic syndrome, and diabetes. Urological and medical assessments should be performed to diagnose nocturia disorder. A frequency volume chart to evaluate the nocturnal polyuria index, functional bladder capacity, and urodynamic study can reveal the presence of nocturnal polyuria and lower urinary tract dysfunction. Treatment should be based on multiple nocturia etiologies, and a combination of multiple therapies for individual pathophysiology will achieve a better treatment outcome.

KEYWORDS: *Bladder outlet obstruction, Lower urinary tract dysfunction, Nocturnal incontinence, Urinary frequency*

INTRODUCTION

Lower urinary tract symptoms (LUTS) are bothersome in older people. Among the LUTS, the prevalence of nocturia is not higher than that of hesitancy, intermittency, and incomplete emptying; however, the percentage of patients who perceive it as more than just a problem is as high as 70% [1]. Nocturia is defined as frequent waking to void for one or more times [1,2]. The prevalence of nocturia is high in men and women and increases with aging with much higher rates in those aged >60 years [3], and nocturia significantly affects the quality of life (QoL) and even increases mortality [4,5].

Epidemiological studies have revealed that nocturia is positively associated with depressive syndrome [6]. Patients with metabolic syndrome and smoking may have persistent nocturia after transurethral resection of the prostate [7]. The improvement of nocturia episodes in the International Prostate Symptom Score (IPSS) has been found to have a maximal influence on the change in the QoL score in patients with LUTS [8]. A community health survey in Boston also revealed that nocturia is significantly associated with increased bothersome and depressive symptoms and QoL [9]. This article reviews recent evidence on the pathophysiology and treatment of nocturia, nocturnal polyuria, and nocturnal enuresis in adults.

CLINICAL CHARACTERISTICS OF NOCTURIA

Clinical characteristics of nocturia include nocturnal frequency of two or more episodes per night, which is found in 49.4% of patients with LUTS, including 32.9% with one episode and 16.5% with two or more episodes [10]; nocturnal polyuria and nocturnal urinary incontinence [11]; global polyuria with day and night polyuria of >40 mL/kg/24 h [12]; and decreased global or nocturnal bladder capacity [13]. Poor sleep quality is also involved in the nocturia pathophysiology. Nocturnal polyuria is defined as having a nocturnal urine output of >90 mL/h or a nocturnal polyuria index (NPI) of >33% of daily urine [11]. Using a frequency volume chart to record daytime and nighttime urinary frequency and voided volume is a pivotal tool in the clinical assessment of nocturia, nocturnal polyuria, and reduced bladder capacity and helps detect urological and nonurological etiologies [2].

The pathophysiology underlying nocturia is multifactorial [14]. Any systemic disease or lower urinary tract dysfunction affecting

***Address for correspondence:** Dr. Hann-Chorng Kuo,
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi
Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan.
E-mail: hck@tzuchi.com.tw

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Chang TL, Kuo HC. Nocturia, nocturnal polyuria, and nocturnal enuresis in adults: What we know and what we do not know. Tzu Chi Med J 2024;36(4):370-6.

Access this article online

Quick Response Code:



Website: www.tcmjmed.com

DOI: 10.4103/tcmj.tcmj_53_24

urothelial cell function, receptor sensitivity, circadian rhythm, chronic inflammation, or oxidative stress can cause nocturia [15]. Therefore, the possible nocturia pathophysiology includes detrusor overactivity, bladder hypersensitivity, bladder outlet obstruction (BOO), nocturnal polyuria, small bladder capacity and contracted bladder, anxiety and depression, sleep disorder and insomnia, and medical diseases such as diabetes mellitus, congestive heart failure, chronic obstructive pulmonary disease, and chronic kidney disease (CKD).

Nocturia in the geriatric population

The prevalence of nocturia increases with age, with a prevalence of >50% in patients aged 80 years [1,4]. Nocturia is also the most common cause of disturbed sleep patterns in older people [16]. Due to sleeping time deprivation, older patients with nocturia are likely to experience fatigue and are exposed to serious health risks [17]. Traumatic injury due to falling also increases in elderly patients with nocturia [18]. Patients with overactive bladder syndrome (OAB) usually strongly desire to void at daytime or during sleep [19]. Patients with OAB due to idiopathic etiology, BOO, central nervous system diseases, or systemic diseases affecting the bladder are often bothered by nocturia with or without nocturnal polyuria. OAB is also positively associated with circadian syndrome in adults in the USA [20]. Medical or minimally invasive treatment for OAB can also effectively decrease nocturia episodes [21].

PATHOPHYSIOLOGY ASSOCIATED WITH NOCTURIA

Benign prostatic hyperplasia and nocturia

Benign prostatic hyperplasia (BPH) should be first considered in older male patients with LUTS and nocturia; thus, they were prescribed alpha blockers to relieve BOO. Patients with BPH with storage symptoms posttreatment with alpha blockers could have improved LUTS after adding on OAB medication or desmopressin [22]. However, the improvement of nocturia episodes in men treated for 2 years was only significant in men aged <80 years, and 62% of patients treated with alpha blockers and 5-alpha-reductase inhibitors still had nocturia more than twice [23]. This result further implies that nocturia in elderly men is caused by several factors other than BPH or BOO. The common causes of nocturia unrelated to BOO include nocturnal polyuria, idiopathic detrusor overactivity, reduced bladder capacity, or bladder hypersensitivity with aging [15]. In patients with unimproved nocturia after a combined alpha-blocker and antimuscarinic therapy for clinical BPH, detailed examinations for persistent BOO, nocturnal polyuria, neurogenic OAB, or inflammatory bladder dysfunction should be performed to identify the etiologies and provide appropriate treatment [24].

Hypertension and nocturia

Hypertension is highly prevalent in older people. The association between nocturia and hypertension has been widely reported but poorly characterized [25]. Nocturia has been reported in various systemic diseases, including diabetes, cardiovascular disease, and hypertension. Elevated blood pressure was strongly associated with nocturia as determined by both voiding diary and self-report, with renal

hyperperfusion as the main mechanism [26]. The Nagahama study revealed that nocturia may represent a potential risk for circadian bladder pressure abnormality, with a slight nocturnal blood pressure drop in participants with nocturia [27]. Nocturia may be a marker for cardiovascular disease risks. Frequent nocturnal urination was independently associated with arterial stiffness measured by the brachial-to-ankle pulse wave velocity in older men [28]. Inadequate reduction of nocturnal blood pressure has been associated with nocturnal polyuria in men [29]. Silodosin has been reported as an effective treatment for male LUTS, including nocturia, in men with clinical BPH, possibly related to a reduction of nocturnal blood pressure [30].

Cardiovascular, kidney, and pulmonary diseases and nocturia

In addition to hypertension, heart disease, especially congestive heart failure (CHF), is closely associated with nocturia, typically nocturnal polyuria [31]. The atrial natriuretic peptide levels were elevated in patients with CHF and nocturnal polyuria. Patients with nocturia and high plasma levels of atrial natriuretic peptide might have subclinical heart failure and should be referred for cardiologic treatment [32]. CKD is also a risk factor for developing nocturnal polyuria through the osmotic diuresis mechanism. Reduced renal function could impair salt and water homeostasis, causing nocturnal polyuria and hence nocturia in patients with CKD [33]. Treatment of nocturnal polyuria in patients with CKD should aim at reducing salt intake, promoting fluid control, and identifying urological diseases. In patients with obstructive sleep apnea syndrome (OSAS), nocturia is a symptom that increases the disturbance with disease severity [34]. Patients with OSAS are easily awake and have increased bladder filling due to polyuria. Treatment with continuous positive airway pressure can reduce the nocturia episode by one or more voids and improve the QoL of patients with OSAS [35].

Dietary salt control is important in patients with salt-sensitive hypertension and nocturia [36]. When patients consume too much salty food during daytime and cannot excrete salt, they are likely to excrete salt at nighttime, causing increased urine output during sleeping time and resulting in nocturia. In patients with CHF, a supine position during sleep further increases central fluid volume by increasing venous return, stretching the atria and ventricles, and increasing atrial natriuretic peptide. Treatment with thiazide and loop diuretics in the morning may be effective in reducing nocturia and nocturnal urine output. A small functional bladder capacity may exacerbate the nocturia severity, particularly in older people with CHF, CKD, or OSAS [37].

Diabetes, metabolic syndrome, and nocturia

Diabetes is strongly associated with nocturia [38]. Sleep and circadian rhythm disturbances are common in people with diabetes, which are associated with an increased risk of developing type 2 diabetes and poor treatment outcomes. Appropriate treatment of disturbed sleep and circadian rhythm could improve diabetes outcomes [39]. Nocturia is also positively associated with depression in Japanese women with

type 2 diabetes [6]. Metabolic syndrome is defined by a group of cardiovascular risk factors, including impaired glucose tolerance, central obesity, hypertension, and dyslipidemia. Metabolic syndrome is also associated with LUTS, especially nocturia [40]. OAB is more prevalent in patients with metabolic syndrome than in controls [41]. The common pathophysiology of OAB and metabolic syndrome includes autonomic dysregulation, chronic ischemia, inflammation, and dysregulation of nutrient-sensing pathways [42]. Patients with OAB refractory to currently available medications should be appropriately managed by targeting metabolic syndrome.

Poor sleep pattern and nocturia

Nocturia is bidirectionally associated with depression [43]. A previous study reported that moderate-to-severe depression is prevalent in women with OAB, mainly associated with urgency incontinence and nocturia [44]. Many, but not all, women with OAB experienced interrupted sleep due to bladder symptoms. Some women had nocturia due to poor sleep quality because of anxiety or depression [45]. Therefore, clinicians should not conclude that all nocturia is caused by bladder symptoms. Among women with urgent urinary incontinence, poor sleep quality is common, and these patients should be queried about their sleep patterns [46]. In addition to antimuscarinic agents prescribed for OAB, appropriate intervention for poor sleep patterns should be concomitantly offered.

Nocturnal polyuria

Nocturia can be caused by high fluid intake, nephrological, cardiovascular, hormonal, urological, or sleep factors [47]. For patients with nocturia not responding to the first medical treatment for OAB or BOO, nocturnal polyuria should be considered the etiology. Nocturnal polyuria is a condition with excessive urine production at night [1]. Patients with nocturnal polyuria usually have nocturnal urine amounts of >33% of the daily urine amount, termed a NPI of >0.33. In addition to a high NPI, patients generally have abnormal lower urinary tract function such as OAB or BOO, and some may also have medical diseases causing polydipsia or osmotic diuresis [48]. The common pathophysiology of nocturia and nocturnal polyuria is listed in Table 1.

TREATMENT OF NOCTURIA AND NOCTURNAL POLYURIA

Patients with nocturia which affects the sleep quality and bothersome should be treated. Treatment of nocturia should start with lifestyle modification and behavioral changes, followed by medication for underlying medical or urological conditions, including OAB, BOO, poor sleep pattern, nocturnal polyuria, and medical diseases [49]. The treatment strategy should include the following: (1) water restriction for patients with polydipsia and salt restriction for hypertension; (2) good control of diabetes, hypertension, CHF, CKD, or OSAS; (3) tranquilizer for insomnia and consultation with a psychiatrist for poor sleep patterns; (4) treatment of BPH and BOO, if any, with alpha-blockers with or without 5-alpha-reductase inhibitors; (5) addition of antimuscarinics or beta-3 adrenoceptor agonists; (6) addition

Table 1: Common causes and pathophysiology of nocturia and nocturnal polyuria

Cause of nocturnal polyuria	Underlying pathophysiology
Poor sleep pattern	Mental or physical ill health
LUTD	Incomplete voiding
	Bladder outlet obstruction
	Detrusor underactivity
	Bladder overactivity
	Bladder hypersensitivity
	Neurogenic LUTD
Excessive fluid output	Primary polydipsia
	Drugs, diuretics, alcohol, and caffeine
	Circadian changes to arginine vasopressin secretion
	Diabetes insipidus, DM
	Hypercalcemia, hyperuricosemia

DM: Diabetes mellitus, LUTD: Lower urinary tract dysfunction

of desmopressin or afternoon diuretics for nocturnal polyuria; and (7) combination therapy for patients with multiple factors. Personalized treatment is essential based on patients' age, sex, medical comorbidity, and underlying pathophysiology [49,50] [Table 1]. Because the nocturia pathophysiology is usually multifactorial, medical treatment for LUTS in men with nocturia is usually not significantly better than placebo [51]. However, efforts should be made to find the appropriate medication or treatment for nocturia after the first trial has failed.

Desmopressin

If the voiding diary has revealed the presence of nocturnal polyuria (NPI, ≥ 0.33), antidiuretic therapy can effectively reduce nocturnal urine production and hence decrease the nocturia episodes [48]. Currently, desmopressin is the only synthetic analog of arginine-vasopressin specifically indicated for patients with nocturnal polyuria [50]. In a Japanese multicentric clinical study, desmopressin of 25 and 50 μg had been shown effective for male patients with nocturnal polyuria. Nocturia episodes decreased from 4.1 ± 1.3 at baseline to 2.9 ± 1.4 at 1 month ($P < 0.01$) and 2.6 ± 1.3 at 23 months ($P < 0.01$). Patients with nocturia reduction of two or more episodes had larger nighttime voided volume at baseline [52]. Our previous study also confirmed that 66.7% of patients aged >65 years with severe nocturnal polyuria were effectively treated with desmopressin. Nocturnal frequency decreased from 5.2 ± 1.16 at baseline to 2.24 ± 1.12 times at 1 month, and nocturnal urine volume decreased from 955.6 ± 255.9 mL at baseline to 522.8 ± 210.5 mL at 1 month. The posttreatment nocturnal bladder capacity also increased in patients effectively treated but not in those who failed treatment. The adverse event of hyponatremia was noted in only 1 (3.3%) patient [53].

Recently, low-dose oral desmopressin has been used for the treatment of men with nocturia associated with BPH. A systematic review revealed desmopressin alone or in combination with an alpha blocker effectively reduced nocturia in 43% and 64.3% of men with LUTS and nocturia, respectively [54]. Another systematic review confirmed the

efficacy of desmopressin in improving nocturia, QoL, and IPSS storage subscore. However, short-term adverse events such as nausea, headache, dizziness, and hyponatremia should be cautiously monitored [55]. However, a comprehensive review revealed that the efficacy of reducing nighttime frequency is similar to that of alpha blockers, and the combination of desmopressin with an alpha blocker or antimuscarinic agent did not provide additional benefits in the treatment of nocturia defined as one or more voids per night [56]. The treatment algorithm for nocturia and nocturnal polyuria is shown in Figure 1.

Due to potential adverse events of hyponatremia for the treatment with desmopressin, especially in patients aged >65 years, patients treated with desmopressin should be cautiously monitored for serum sodium levels [57]. The International Continence Society consensus on the diagnosis and treatment of nocturia has declared that serum sodium should be monitored at days 3–7 and 1 month, desmopressin therapy should be stopped if the serum sodium level is <130 mmol/L regardless of symptoms, and the treatment should be terminated if the serum sodium level is 130–135 mmol/L with symptoms of hyponatremia.

Nonpharmacological treatment of sleep quality in patients with nocturia

Several nonpharmacological treatments have been developed or applied to treat OAB and improve the sleep quality in women with OAB and nocturia. The treatments include pelvic floor muscle training [58], posterior tibial nerve stimulation [59,60], and percutaneous tibial nerve stimulation [61]. Nonpharmacological treatments using either method were equally effective in improving the sleep quality of women with nocturia [62].

Another nonpharmacological treatment for nocturia is continuous positive airway pressure (CPAP) devices. Patients with OSAS can be effectively treated with CPAP, and

nocturia decreases by one or more episodes [35]. Urodynamic detrusor overactivity also decreased, and bladder compliance increased after the CPAP treatment [63]. A combination of the antimuscarinic agent tolterodine with CPAP could provide beneficial efficacy in OAB symptoms but not daily urine volume compared with CPAP treatment alone [64].

NOCTURNAL ENURESIS AND URINARY INCONTINENCE IN ADULTS

Nocturnal enuresis is commonly encountered in children aged <5 years. Nocturia is a maturation defect due to the lack of the circadian rhythm of arginine-vasopressin, resulting in urine overproduction during sleep [65]. In addition to nocturnal polyuria in children, other factors contribute to nocturnal enuresis in children, causing 20%–60% of children with monosymptomatic enuresis to be desmopressin-resistant [66]. In children with desmopressin-responsive nocturnal enuresis, nocturnal urine volume is greater at nights than at nights without enuresis, indicating other factors contributing to the occurrence of enuresis during sleep, such as high salt and water intake, deep sleep, and detrusor overactivity [67].

In older men and women with nocturnal urinary incontinence, increased nocturnal sodium diuresis and nocturnal polyuria are significant findings compared with those without nocturnal LUTS [68]. From the frequency volume chart, 84% of patients with nocturia can be categorized, and 95% of patients aged 60–80 years with nocturia can be categorized using a voiding diary and urodynamic study [69]. Among patients with nocturnal urinary incontinence, BOO due to BPH in men and dysfunctional voiding in women, detrusor overactivity, neurogenic OAB due to stroke and Parkinson's disease, and detrusor underactivity and overflow urinary incontinence after radical hysterectomy or abdominoperineal resection of the rectum are common diseases [70,71]. In addition, secondary causes of nocturnal enuresis, such as psychological distress, and contracted bladder with low




Figure 1: Diagnostic and treatment algorithm for adults with nocturia, nocturnal polyuria, and nocturnal enuresis. IPSS: International Prostate Symptom Score, OABSS: Overactive Bladder Symptom Score, NPI: Nocturnal polyuria index, LUTS: Lower urinary tract symptoms, LUTD: Lower urinary tract dysfunction, 5-ARI: 5-alpha-reductase inhibitor, PFMT: Pelvic floor muscle training, SSRI: Selective serotonin reuptake inhibitor, DM: Diabetes mellitus, CHF: Congestive heart failure, CKD: Chronic kidney disease, COPD: Chronic obstructive pulmonary disease, H/T: Hypertension, CPAP: Continuous positive airways pressure

bladder compliance are also possible causes of nocturnal urinary incontinence in adults [72,73].

Treatment for adult-onset nocturnal enuresis is similar to that for nocturia in adults. All patients with adult-onset nocturnal enuresis should be thoroughly worked up to identify possible etiologies of urinary incontinence, such as obesity, neurogenic disorders, bladder storage, and emptying dysfunction, by frequency volume chart, urodynamic study, neurological examinations, and cystoscopy [74,75]. Patients proven to have nocturnal polyuria should be treated with desmopressin. Antimuscarinic agents, such as tolterodine or solifenacin, can be added in patients with daytime and nighttime urinary incontinence. If a urodynamic study revealed BOO due to bladder neck dysfunction, BPH, or dysfunctional voiding, appropriate medication or surgical procedures are recommended. Imipramine or methylephedrine is helpful in male or female patients suspected of urethral sphincter incompetence. Pelvic floor muscle exercise or functional electrostimulation may also be helpful if medical treatment fails [76].

FUTURE RESEARCH TOPICS FOR NOCTURIA AND NOCTURNAL ENURESIS

Although extensive research has been performed to understand the pathophysiology of nocturia, nocturnal polyuria, and nocturnal enuresis in adults, several important questions remain to be solved. The role of desmopressin in adult nocturia without nocturnal polyuria should be determined. Will desmopressin affect bladder sensation, detrusor overactivity, or nocturnal urine output through unknown receptors in the bladder urothelium or kidney? How does desmopressin improve functional bladder capacity in patients who respond to treatment? Will bladder conditions such as detrusor overactivity change in pediatric nocturnal enuresis after long-term desmopressin therapy? What are the predictive factors for successful or failed desmopressin treatment for nocturia and nocturnal polyuria in adult patients? Will a combination of desmopressin and selective serotonin reuptake inhibitor have better therapeutic efficacy in adult primary nocturnal enuresis? All these questions deserve further clinical research to provide a better framework for the more effective treatment of adult nocturia.

CONCLUSION

Nocturia, nocturnal polyuria, and nocturnal enuresis in adults cause disturbed LUTS and are difficult to treat with currently available medications. Several different etiologies have been identified for nocturia disorders, including dietary imbalance, poor sleep quality, bladder storage and emptying dysfunctions, nocturnal polyuria due to vasopressin deficiency or secondary to medical diseases, and psychological distress. Detailed examination should be performed to identify possible causes and select appropriate treatment, including behavioral and lifestyle modification, appropriate medications, physiotherapy, and nonpharmacological therapies, to improve the QoL of adults with nocturia disorders.

Data availability statement

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Financial support and sponsorship

This study was supported by grants from the Tzu Chi Medical Foundation, TCMF-SP-112-01, and TCMF-MP-110-03-01.

Conflicts of interest

Dr. Hann-Chorng Kuo, an editorial board member at *Tzu Chi Medical Journal*, had no role in the peer review process or the decision to publish this article. The other author declared no conflicts of interest in writing this paper.

REFERENCES

- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. *Neurourol Urodyn* 2002;21:167-78.
- Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, et al. A contemporary assessment of nocturia: Definition, epidemiology, pathophysiology, and management – A systematic review and meta-analysis. *Eur Urol* 2012;62:877-90.
- Pesonen JS, Cartwright R, Mangera A, Santti H, Griebeling TL, Pryalukhin AE, et al. Incidence and remission of nocturia: A systematic review and meta-analysis. *Eur Urol* 2016;70:372-81.
- Jackson S. Lower urinary tract symptoms and nocturia in men and women: Prevalence, aetiology and diagnosis. *BJU Int* 1999;84(Suppl 1):5-8.
- Pesonen JS, Cartwright R, Vernooij RW, Aoki Y, Agarwal A, Mangera A, et al. The impact of nocturia on mortality: A systematic review and meta-analysis. *J Urol* 2020;203:486-95.
- Furukawa S, Sakai T, Niiya T, Miyaoka H, Miyake T, Yamamoto S, et al. Nocturia and prevalence of depressive symptoms in Japanese adult patients with type 2 diabetes mellitus: The Dogo study. *Can J Diabetes* 2018;42:51-5.
- De Nunzio C, Tema G, Lombardo R, Cicione A, Nacchia A, D'Annunzio S, et al. Metabolic syndrome and smoking are associated with persistence of nocturia after transurethral resection of the prostate. *Neurourol Urodyn* 2019;38:1692-9.
- Choi WS, Son H. The change of IPSS 7 (nocturia) score has the maximum influence on the change of QoL score in patients with lower urinary tract symptoms. *World J Urol* 2019;37:719-25.
- Kupelian V, Wei JT, O'Leary MP, Norgaard JP, Rosen RC, McKinlay JB. Nocturia and quality of life: Results from the Boston area community health survey. *Eur Urol* 2012;61:78-84.
- Clemens JQ, Wiseman JB, Smith AR, Amundsen CL, Yang CC, Bradley MS, et al. Prevalence, subtypes, and correlates of nocturia in the symptoms of lower urinary tract dysfunction research network cohort. *Neurourol Urodyn* 2020;39:1098-107.
- Monaghan TF, Epstein MR, Bliwise DL, Michelson KP, Wu ZD, Lazar JM, et al. Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome. *Neurourol Urodyn* 2020;39:785-92.
- Monaghan TF, Rahman SN, Bliwise DL, Michelson KP, Agudelo CW, Miller CD, et al. Identifying men with global polyuria on a nocturnal-only voiding diary. *Neurourol Urodyn* 2020;39:347-52.
- Yoon JH, Lee K, Park EJ, Kwon T, Park S, Moon KH, et al. Analysis of changes in the pathophysiology of nocturia according to the number of nocturia episode, age, and gender using frequency volume charts: A retrospective observational study. *Medicine (Baltimore)* 2022;101:e31295.

14. Kujubu DA, Aboseif SR. An overview of nocturia and the syndrome of nocturnal polyuria in the elderly. *Nat Clin Pract Nephrol* 2008;4:426-35.
15. Birdier LA, Van Kerrebroeck PE. Pathophysiological mechanisms of nocturia and nocturnal polyuria: The contribution of cellular function, the urinary bladder urothelium, and circadian rhythm. *Urology* 2019;133S:14-23.
16. Shao IH, Wu CC, Hsu HS, Chang SC, Wang HH, Chuang HC, et al. The effect of nocturia on sleep quality and daytime function in patients with lower urinary tract symptoms: A cross-sectional study. *Clin Interv Aging* 2016;11:879-85.
17. Miller M. Nocturnal polyuria in older people: Pathophysiology and clinical implications. *J Am Geriatr Soc* 2000;48:1321-9.
18. Noguchi N, Chan L, Cumming RG, Blyth FM, Naganathan V. A systematic review of the association between lower urinary tract symptoms and falls, injuries, and fractures in community-dwelling older men. *Aging Male* 2016;19:168-74.
19. Abu Mahfouz I, Asali F, Abdel Razeq R, Ibraheem R, Abu Mahfouz S, Jaber H, et al. Bladder sensations in women with nocturia due to overactive bladder syndrome. *Int Urogynecol J* 2020;31:1041-8.
20. Xiao Y, Yin S, Wang J, Cui J, Yang Z, Wang J, et al. A positive association between the prevalence of circadian syndrome and overactive bladder in United States adults. *Front Public Health* 2023;11:1137191.
21. Jiang YH, Kuo HC. Current optimal pharmacologic therapies for overactive bladder. *Expert Opin Pharmacother* 2023;24:2005-19.
22. Su YT, Chen HL, Teoh JY, Chan VW, Wu WJ, Lee HY. Comparison of add-on medications for persistent storage symptoms after α -blocker treatment in BPH patients – A network meta-analysis. *BMC Urol* 2023;23:154.
23. Malde S, Patel A, Martínez Piñeiro L, de la Taille A, Bjartell A, Tubaro A, et al. Incidence of nocturia in men with lower urinary tract symptoms associated with benign prostatic enlargement and outcomes after medical treatment: Results from the evolution European Association of Urology research foundation prospective multinational registry. *Eur Urol Focus* 2021;7:178-85.
24. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. *Eur Urol* 2006;49:651-8.
25. Rahman SN, Cao DJ, Monaghan TF, Flores VX, Vaysblat M, Moy MW, et al. Phenotyping the association between nocturia and hypertension: A systematic review and meta-analysis. *J Urol* 2021;205:1577-83.
26. Promi T, Tologonova G, Roberts MC, Tena M, Dhuper S, Bamgbola O, et al. Nocturia and blood pressure elevation in adolescents. *J Community Health* 2024;49:379-84.
27. Matsumoto T, Tabara Y, Murase K, Setoh K, Kawaguchi T, Nagashima S, et al. Nocturia and increase in nocturnal blood pressure: The Nagahama study. *J Hypertens* 2018;36:2185-92.
28. Tabara Y, Matsumoto T, Murase K, Setoh K, Kawaguchi T, Nagashima S, et al. Frequent nocturnal urination in older men is associated with arterial stiffness: The Nagahama study. *Hypertens Res* 2019;42:1996-2001.
29. Kato Y, Akaiha H, Takezawa K, Maekawa S, Matsuoka K, Fukuhara S, et al. Association between nocturnal polyuria and 24-h blood pressure fluctuations in males with lower urinary tract symptoms: A multicenter prospective study. *Int J Urol* 2024;31:259-64.
30. Cho KJ, Lee JZ, Song YS, Choi JB, Kim DK, Kim YT, et al. Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: A multicenter, prospective, open-label, single-arm, phase IV trial. *Urology* 2018;121:153-7.
31. Lombardo R, Tubaro A, Burkhard F. Nocturia: The complex role of the heart, kidneys, and bladder. *Eur Urol Focus* 2020;6:534-6.
32. Fujikawa K, Kasahara M, Matsui Y, Takeuchi H. Human atrial natriuretic peptide is a useful criterion in treatment of nocturia. *Scand J Urol Nephrol* 2001;35:310-3.
33. Ridgway A, Cotterill N, Dawson S, Drake MJ, Henderson EJ, Huntley AL, et al. Nocturia and chronic kidney disease: Systematic review and nominal group technique consensus on primary care assessment and treatment. *Eur Urol Focus* 2022;8:18-25.
34. Di Bello F, Napolitano L, Abate M, Collà Ruvo C, Morra S, Califano G, et al. Nocturia and obstructive sleep apnea syndrome: A systematic review. *Sleep Med Rev* 2023;69:101787.
35. Vrooman OP, van Balken MR, van Koeveeringa GA, van Kerrebroeck PV, Driessen LE, Schouten LJ, et al. The effect of continuous positive airway pressure on nocturia in patients with obstructive sleep apnea syndrome. *Neurourol Urodyn* 2020;39:1124-8.
36. Ohishi M, Kubozono T, Higuchi K, Akasaki Y. Hypertension, cardiovascular disease, and nocturia: A systematic review of the pathophysiological mechanisms. *Hypertens Res* 2021;44:733-9.
37. Monaghan TF, Miller CD, Agudelo CW, Rahman SN, Everaert K, Birdier LA, et al. Cardiovascular risk independently predicts small functional bladder storage capacity. *Int Urol Nephrol* 2021;53:35-9.
38. Fu Z, Wang F, Dang X, Zhou T. The association between diabetes and nocturia: A systematic review and meta-analysis. *Front Public Health* 2022;10:924488.
39. Rutters F, Nefs G. Sleep and circadian rhythm disturbances in diabetes: A narrative review. *Diabetes Metab Syndr Obes* 2022;15:3627-37.
40. Aoki Y, Yokoyama O. Metabolic syndrome and nocturia. *Low Urin Tract Symptoms* 2012;4(Suppl 1):11-5.
41. Saratlija Novakovic Z, Tesija RA, Puljak L. Association between metabolic syndrome and overactive bladder: A case-control study. *Scand J Urol* 2017;51:470-3.
42. Hsu LN, Hu JC, Chen PY, Lee WC, Chuang YC. Metabolic syndrome and overactive bladder syndrome may share common pathophysiologies. *Biomedicines* 2022;10:1957.
43. Breyer BN, Shindel AW, Erickson BA, Blaschko SD, Steers WD, Rosen RC. The association of depression, anxiety and nocturia: A systematic review. *J Urol* 2013;190:953-7.
44. Melotti IG, Juliato CR, Tanaka M, Riccetto CL. Severe depression and anxiety in women with overactive bladder. *Neurourol Urodyn* 2018;37:223-8.
45. Savoie MB, Lee KA, Subak LL, Hernandez C, Schembri M, Fung CH, et al. Beyond the bladder: Poor sleep in women with overactive bladder syndrome. *Am J Obstet Gynecol* 2020;222:600.e1-13.
46. Winkelman WD, Warsi A, Huang AJ, Schembri M, Rogers RG, Richter HE, et al. Sleep quality and daytime sleepiness among women with urgency predominant urinary incontinence. *Female Pelvic Med Reconstr Surg* 2018;24:76-81.
47. Kim J, Chung E. Pharmacotherapeutic options in the treatment of nocturia: An update on the current oral drug therapies. *Expert Opin Pharmacother* 2022;23:405-11.
48. Weiss JP, Everaert K. Management of nocturia and nocturnal polyuria. *Urology* 2019;133S: 24-33.
49. Andersson KE, Van Kerrebroeck P. Pharmacotherapy for nocturia. *Curr Urol Rep* 2018;19:8.
50. Chung E. Desmopressin and nocturnal voiding dysfunction: Clinical evidence and safety profile in the treatment of nocturia. *Expert Opin Pharmacother* 2018;19:291-8.
51. Sakalis VI, Karavitakis M, Bedretinova D, Bach T, Bosch JL, Gacci M, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: Systematic review by the European Association of Urology guidelines panel for male lower urinary tract symptoms. *Eur Urol* 2017;72:757-69.
52. Kyoda Y, Kimura M, Shimizu T, Miyao N, Ogasawara T, Shimizu T, et al. Efficacy and safety of desmopressin orally disintegrating tablets 25 and 50 μ g in male patients with nocturia: A Japanese real-world multicenter clinical study. *Low Urin Tract Symptoms* 2022;14:410-5.

53. Kuo HC. Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. *Urology* 2002;59:485-9.
54. Taha DE, Aboumarzouk OM, Shokeir AA. Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature. *Arab J Urol* 2018;16:404-10.
55. Wang Q, Alshayyah R, Yang B. The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis. *Low Urin Tract Symptoms* 2022;14:155-62.
56. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. Desmopressin for treating nocturia in men. *Cochrane Database Syst Rev* 2017;10:CD012059.
57. Everaert K, Hervé F, Bosch R, Dmochowski R, Drake M, Hashim H, et al. International Continence Society consensus on the diagnosis and treatment of nocturia. *Neurourol Urodyn* 2019;38:478-98.
58. Fitz F, Sartori M, Girão MJ, Castro R. Pelvic floor muscle training for overactive bladder symptoms – A prospective study. *Rev Assoc Med Bras* (1992) 2017;63:1032-8.
59. Ridout AE, Yoong W. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy. *J Obstet Gynaecol* 2010;30:111-4.
60. Bhide AA, Tailor V, Fernando R, Khullar V, Digesu GA. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. *Int Urogynecol J* 2020;31:865-70.
61. Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. *J Urol* 2013;189:2194-201.
62. Furtado-Albانهzi D, Jürgensen SP, Avila MA, Correia GN, Driusso P. Effects of two nonpharmacological treatments on the sleep quality of women with nocturia: A randomized controlled clinical trial. *Int Urogynecol J* 2019;30:279-86.
63. Fernández Pello S, Gil R, Escaf S, Rodríguez Villamil L, Alzueta A, Rodríguez C, et al. Lower urinary tract symptoms and obstructive sleep apnea syndrome: Urodynamic evolution before and after one year of treatment with continuous positive airway pressure. *Actas Urol Esp (Engl Ed)* 2019;43:371-7.
64. Ertaş K, Yıldız H, Demir M, Aslan R, Eryılmaz R, Kırmızıtoprak Ş, et al. Effect of combined use of tolterodine and continuous positive airway pressure versus continuous positive airway pressure only treatment on overactive bladder symptoms in women with moderate-to-severe obstructive sleep apnea syndrome: A randomized clinical trial. *Int Urogynecol J* 2022;33:2031-6.
65. Kamperis K. Nocturnal enuresis in children: The role of arginine-vasopressin. *Handb Clin Neurol* 2021;181:289-97.
66. Dossche L, Walle JV, Van Herzele C. The pathophysiology of monosymptomatic nocturnal enuresis with special emphasis on the circadian rhythm of renal physiology. *Eur J Pediatr* 2016;175:747-54.
67. Rittig S, Schaumburg HL, Siggaard C, Schmidt F, Djurhuus JC. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. *J Urol* 2008;179:2389-95.
68. Denys MA, Decalf V, Kumps C, Petrovic M, Goessaert AS, Everaert K. Pathophysiology of nocturnal lower urinary tract symptoms in older patients with urinary incontinence. *Int J Urol* 2017;24:808-15.
69. Bing MH, Moller LA, Jennum P, Mortensen S, Lose G. Pathophysiological aspects of nocturia in a danish population of men and women age 60 to 80 years. *J Urol* 2007;178:552-7.
70. Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, Farag F, et al. European association of urology guidelines on the management of female non-neurogenic lower urinary tract symptoms. Part 2: Underactive bladder, bladder outlet obstruction, and nocturia. *Eur Urol* 2022;82:60-70.
71. Haddad R, Denys P, Arlandis S, Giannantoni A, Del Popolo G, Panicker JN, et al. Nocturia and nocturnal polyuria in neurological patients: From epidemiology to treatment. A systematic review of the literature. *Eur Urol Focus* 2020;6:922-34.
72. Wang TM, Yang SS, Tsai JD, Yu MC, Chiou YH, Chen KL, et al. Management of nocturnal enuresis in Taiwan: Consensus statements of the Taiwan enuresis expert committee. *J Formos Med Assoc* 2019;118:965-72.
73. Sakamoto K, Blaivas JG. Adult onset nocturnal enuresis. *J Urol* 2001;165:1914-7.
74. Katz EG, MacLachlan LS. Nocturnal enuresis in the adult. *Curr Urol Rep* 2020;21:31.
75. Song QX, Wang L, Cheng X, Hao Y, Liu Z, Abrams P. The clinical features and predictive factors of nocturnal enuresis in adult men. *BJU Int* 2020;126:472-80.
76. Song QX, Li J, Gu Y, Xu L, Abrams P, Xue W. The clinical features and predictive factors of nocturnal enuresis in adult women. *Front Med (Lausanne)* 2021;8:744214.